2025年3月4日 · Zyvac Tcv-PFS Vaccine is a vaccine which helps develop immunity by initiating a mild infection. This type of infection does not cause illness but stimulates the body's immune system to produce antibodies (proteins) to protect against any future infections.

4.1 Therapeutic indications ZyVac® TCV is indicated for the active immunization against Salmonella typhi infection in 6 months to 65 years age group.

ZyVac® TCV is a sterile, clear and colorless liquid free from visible particles containing Purified Vi-Capsular Polysaccharide of Salmonella typhi which is chemically conjugated to Tetanus Toxoid as carrier protein. ZyVac® TCV is provided in a 5-dose presentation (2.5mL) and each dose (0.5mL) contains:

Typbar-TCV (Bharat Biotech) and Zyvac TCV (Zydus Lifesciences Ltd) are TCVs that have been extensively studied for their safety and immunogenicity. Both vaccines have demonstrated a favorable safety profile and are well-tolerated.

Vi Capsular Polysaccharide Tetanus Toxoid Conjugate Vaccine (ZyVac-TCV), manufactured by Cadila Healthcare Limited, India, is the most recently licensed TCV. A Phase II/III study to demonstrate the noninferiority of ZyVac-TCV to Typbar TCV in healthy individuals aged 6 months to 45 years was initiated in 2016 [60].

ZyVac ® TCV 是在艾哈迈达巴德 Zydus 生物技术园自主开发和生产的。 ZyVac ® TCV 适用于 6 个月至 65 岁年龄段人群的伤寒沙门氏菌感染主动免疫。 ZyVac ® TCV 的这项预审资格使其有资格成为联合国机构采购计划的一部分。 联合国机构每年采购超过1.5亿剂伤寒结合疫苗，用于在印度、非洲和东南亚等伤寒流行地区预防这种传染病。 伤寒（Typhoid fever） 是一种全身性发热性疾病，由通过受污染的水和食物摄入伤寒沙门氏菌 (S. typhi) 而引起。 在南亚地区，仅印度就占 …

TCV is now eligible for purchase by United Nations (UN) agencies. ZyVac® TCV is indigenous lmonella typhi infection in the age group of 6 months to 65 years. This prequalification for ZyVac® TCV

ZyVac® TCV contains purified Vi capsular polysaccharide of Salmonella typhi conjugated etanus toxoid as carrier protein. The vaccine confers significant protection against typhoid fever base

This will be a phase III effectiveness study of the typhoid conjugate vaccine (Vi-TCV) (ZyVac® TCV). The study will be conducted in a closed cohort population of children aged 6 months to 15 years residing in a selected geographical catchment area in Dhaka, Bangladesh using a test-negative design (TND).

2024年12月20日 · 这是一项前瞻性封闭队列、开放标签、III 期有效性研究，使用伤寒结合疫苗 ZyVac® TCV（与破伤风类毒素结合作为载体蛋白的纯化 Vi 伤寒沙门氏菌荚膜多糖）的测试阴性设计，...。